Clinical trials: Multiple Primary Neoplasm
Solid Tumor
Study of FCN-098 in Patients With Advanced Solid Tumor
A multi-center, open, single-arm phase I dose exploratory study to evaluate the safety, tolerability, pharmacokinetic characteristics and primary antitumor activity of FCN-098 in patients with advanced solid tumors.
- Trial name
- NCT05212987
- Testing
- FCN-098
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Fochon Pharmaceuticals, Ltd.
Anterior Cruciate Ligament Reconstruction
SeriACL™ Device (Gen IB) Trial for Anterior Cruciate Ligament (ACL) Repair
A multi-center single-arm clinical trial is being conducted to evaluate SeriACL device safety and performance during total anterior cruciate ligament (ACL) reconstruction.
- Trial name
- NCT00775892
- Testing
- SeriACL Device ACL Reconstruction
- Where
- 6 sites in Austria, Belgium and 1 more
- Volunteers
- 30 people
- Sponsor
- Serica Technologies, Inc.
Inflammatory Arthritis, Primary Total Knee Arthroplasty Due to Degenerative Joint Disease (Primary Diagnosis of Osteoarthritis)
A Multi-Center Study Assessing the Safety and Efficacy of the LEGION Medial Stabilized (MS) Insert in Patients Undergoing a Total Knee Arthroplasty (TKA)
The purpose of this study is to assess the long-term safety and performance of the LEGION Medial Stabilized insert and to generate clinical evidence to support and maintain product registration in global markets.
- Conditions
- Inflammatory Arthritis, Primary Total Knee Arthroplasty Due to Degenerative Joint Disease (Primary Diagnosis of Osteoarthritis), Post-traumatic Arthritis
- Trial name
- NCT07199738
- Testing
- Cemented CoCr, Cemented Oxinium, Cementless
- Where
- 4 sites in United States
- Volunteers
- 144 people
- Sponsor
- Smith & Nephew, Inc.
Open Angle Glaucoma, Ocular Hypertension
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
This is a Phase III Study that includes a single arm, open-label, multi-dose PK study cohort and a randomized, evaluator-masked, active drug-control multicenter study.
- Trial name
- NCT06666855
- Testing
- DE-117B Eye Drops, Latanoprost
- Where
- 24 sites in China
- Volunteers
- 345 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Multiple System Atrophy
Safinamide for Multiple System Atrophy (MSA)
The study is a placebo controlled study, with two parallel arms, in which participants will be randomly assigned in a 2:1 ratio to receive either active (200 mg safinamide) or placebo in a double blind manner.
- Trial name
- NCT03753763
- Testing
- Safinamide Methanesulfonate
- Where
- 19 sites in Italy, Spain
- Volunteers
- 49 people
- Sponsor
- Zambon SpA
Cancer of Unknown Primary Site
A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site
This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with poor-prognosis cancer of unknown primary site (CUP; non-specific subset) who have…
- Trial name
- CUPISCO (NCT03498521)
- Testing
- Alectinib, Vismodegib, Ipatasertib
- Where
- 125 sites in Australia, Austria and 31 more
- Volunteers
- 529 people
- Sponsor
- Hoffmann-La Roche
Primary Hypercholesterolemia
Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia
The purpose of this study is to investigate the safety and clinical efficacy of HGP1910 and HCP1903 in patients with primary hypercholesterolemia
- Trial name
- NCT04652349
- Testing
- HGP1910, HCP1903, HGP1909
- Where
- South Korea
- Volunteers
- 279 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Multiple Sclerosis
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
The primary objective of this expanded access program is to provide ocrelizumab as treatment for eligible participants with primary progressive multiple sclerosis (PPMS) before it is commercially available in the United States…
- Trial name
- NCT02807285
- Testing
- Ocrelizumab
- Where
- 56 sites in United States
- Sponsor
- Genentech, Inc.
Primary Progressive Multiple Sclerosis, Primary Progressive MS
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.
- Conditions
- Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS)
- Trial name
- NCT07840326
- Testing
- SUN-627
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sundance Biosciences, Inc.
Rheumatoid Arthritis, Osteoarthritis
Multi-Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Resurfacing and Primary Total Hip Replacement
The purpose of this study is to monitor the performance of a large metal-on-metal bearing from the DePuy ASR™ System in the treatment of patients with hip joint disease requiring hip resurfacing surgery or a total hip…
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Post-traumatic Arthritis, Collagen Disorders
- Trial name
- NCT00872547
- Testing
- DePuy ASR™ Hip System, DePuy ASR™ XL Head / ASR™ Acetabular Cup System
- Where
- 8 sites in Austria, Czechia and 6 more
- Volunteers
- 329 people
- Sponsor
- DePuy International
Tuberous Sclerosis Complex
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
The purpose of this study is to investigate the efficacy and safety of NPC-12Y gel compared with placebo for skin lesions associated with tuberous sclerosis.
- Trial name
- NCT05495425
- Testing
- NPC-12Y gel
- Where
- 5 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Nobelpharma
Multiple Myeloma, Primary Plasma Cell Leukemia
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia.
- Trial name
- NCT06333509
- Testing
- CT071
- Volunteers
- 166 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Primary Biliary Cholangitis
A Post-Authorisation Non-Interventional Observational of Patients in France With Primary Biliary Cholangitis Treated With Obeticholic Acid in Real Life
Post-authorisation non-interventional observational study of patients with Primary Biliary Cholangitis who started Ocaliva® treatment between October 1st, 2016 and December 31, 2017.
- Trial name
- OCARELIFE (NCT03703076)
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- SAMEY
Hypotension, Orthostatic
A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension
We are seeking male and female patients to voluntarily take part in a clinical research study. Patients must be aged 18 or older and diagnosed with symptomatic orthostatic hypotension (low blood pressure while in the upright…
- Trial name
- NCT00046163
- Testing
- midodrine hydrochloride (ProAmatine®)
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Shire
Sjogren's Syndrome
A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome
This is a randomized, double-blind, placebo-controlled, two-treatment arm, parallel-group study designed to evaluate the effects of RO5459072 treatment on disease activity and symptoms of Sjogren's syndrome in adult participants…
- Trial name
- NCT02701985
- Testing
- RO5459072
- Where
- 31 sites in United States, France and 4 more
- Volunteers
- 75 people
- Sponsor
- Hoffmann-La Roche
Primary Immunodeficiency
Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency
Approximately 60 subjects will be enrolled in order to have approximately 20 adult subjects and 20 pediatric subjects treated with subcutaneously administered Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography…
- Trial name
- NCT02806986
- Testing
- IGSC 20%
- Where
- 23 sites in Australia, Czechia and 7 more
- Volunteers
- 61 people
- Sponsor
- Grifols Therapeutics LLC
Raynaud's Disease, Peripheral Vascular Disease
PF-00489791 For The Treatment Of Raynaud's
The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
- Trial name
- NCT01090492
- Testing
- PF-00489791
- Where
- 55 sites in United States, Canada and 9 more
- Volunteers
- 243 people
- Sponsor
- Pfizer
C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
The purpose of this study is to evaluate the effectiveness and safety of Pegcetacoplan in patients with C3G and primary IC-MPGN in the real-world setting.
- Trial name
- NCT07746895
- Testing
- Pegcetacoplan
- Where
- 101 sites in Australia, Austria and 12 more
- Volunteers
- 150 people
- Sponsor
- Swedish Orphan Biovitrum
Alport Syndrome, Focal Segmental Glomerulosclerosis
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary…
- Trial name
- NCT05267262
- Testing
- R3R01
- Where
- 22 sites in United States, Belgium and 4 more
- Volunteers
- 43 people
- Sponsor
- River 3 Renal Corp.
Primary Biliary Cirrhosis
Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody
The purpose of the study is to assess safety and efficacy of multiple doses of NI-0801 in primary biliary cirrhosis patients with an inadequate response to ursodeoxycholic acid.
- Trial name
- PIANO (NCT01430429)
- Testing
- NI-0801
- Where
- 2 sites in Italy, United Kingdom
- Sponsor
- Light Chain Bioscience - Novimmune SA